Amazon Takes Another Big Step Toward Getting Into Healthcare

The Motley Fool | September 25, 2019

The tech giant recently launched its own virtual and in-person clinic. Here's why it could be a game-changer. The company acquired online pharmacy Pillpack for nearly $1 billion last June. It formed a joint venture with Berkshire Hathaway and JPMorgan Chase called Haven, which is aiming to disrupt the healthcare system, and the company has loaded its conversational artificial intelligence (AI) Alexa system with healthcare skills, like notifications when prescriptions need to be refilled and information on users' blood sugar levels. This month, Amazon took its biggest dive yet into the $3.7 trillion healthcare industry. The company just launched Amazon Care, a primary-care clinic for Amazon employees in Seattle, accessible at amazon.care. Like Amazon's other big innovations -- including its cloud-computing division Amazon Web Services, its third-party marketplace and fulfillment services, its cashier-less Amazon Go stores, and its fast-growing logistics operation -- Amazon is starting its healthcare initiative by testing it out in-house, serving its own employees first before potentially opening it to the public.

Spotlight

Expose the bony anatomy of the femur and tibia. Prepare the anatomy in the usual fashion by removing as much soft tissue around the femur and tibia as needed to allow for good exposure and optimal Signature MRI-based femoral and tibial positioning guide registration. Register the Signature MRI-based femoral positioning guide on the femur. The Signature MRI-based femoral guide is designed to register in one unique location on cartilage, where present, and on bone where cartilage is absent.


Other News
FUTURE OF HEALTHCARE

Medicago Announces Publication of Phase 3 COVID-19 Vaccine Study Results in New England Journal of Medicine

Medicago | May 06, 2022

Medicago announced the publication of the results from the Phase 3 study of COVIFENZ®, COVID-19 vaccine recombinant, adjuvanted, in the New England Journal of Medicine. The Phase 3 trial studied the two-dose regimen of COVIFENZ® given 21 days apart versus placebo in over 24,000 subjects aged 18 and above. Common side effects in the vaccine group included injection site pain, headache, fatigue, fever, muscle aches, and chills. COVIFENZ® is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 in individuals 18 to 64 years of age. The safety and efficacy of COVIFENZ® in individuals younger than 18 years of age or 65 years and older have not been established. COVIFENZ® has not yet received approval in other jurisdictions. “We are proud to have our Phase 3 clinical trial published in the esteemed New England Journal of Medicine to be shared with the larger scientific community. Medicago’s scientific team has dedicated decades to the development of our proprietary plant-based vaccine manufacturing platform, and we are thrilled to see our results disseminated in this way. We hope that this exchange of research and knowledge will encourage and inspire future innovation in biomedical science and clinical practice.” Marc-André D’Aoust, Executive Vice President, Innovation, Development and Medical Affairs at Medicago COVIFENZ® was authorized for use by Health Canada on February 24, 2022. This is the first authorized COVID-19 vaccine developed by a Canadian-headquartered company, and the first that uses a plant-based protein technology. “The world needs a diverse range of vaccine options to continue to fight COVID-19, and we are proud to be able to contribute,” said Toshifumi Tada, CEO and President at Medicago. About Medicago Medicago is on a mission to help improve global public health using the power of plants. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare, Medicago is a pioneer in plant-based therapeutics. We are proudly rooted in Quebec, with manufacturing capacity in both Canada and the US. Our passionate and curious team of over 500 scientific experts and employees are dedicated to using our technology to provide rapid responses to emerging global health challenges, and to advancing therapeutics against life-threatening diseases worldwide. Medicago is an affiliated company of Mitsubishi Tanabe Pharma Corporation. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation, the majority parent company of Medicago, is one of the large Japanese pharmaceutical companies, with its headquarters in Osaka, Japan. It positions vaccines as one of its key R&D areas and is also working to develop new modalities of vaccines. MTPC will further contribute to the prevention of infectious diseases which is one of the world’s important social issues, by delivering a new option of plant-based VLP vaccine as a new type of vaccine. MTPC is a member of Mitsubishi Chemical Holdings Group.

Read More

HEALTH TECHNOLOGY

CareView Communications Selected to Exhibit Patient Safety System at Vizient Innovative Technology Exchange

CareView Communications, Inc. | June 22, 2022

CareView Communications, Inc. an information technology provider to the healthcare industry, has been selected to exhibit the CareView Patient Safety System®, including its patented, predictive Virtual Bed Rails® and Virtual Chair Rails® technology, at the Vizient Innovative Technology Exchange. Vizient, Inc., the nation’s largest member-driven health care performance improvement company, will hold the Exchange on October 17 at the Renaissance, Dallas. The annual Innovative Technology Exchange offers selected suppliers the unique opportunity to demonstrate their technologies to supply chain and clinical leaders from Vizient’s member hospitals and subject matter experts who serve on its supply councils. Each technology will showcase how it improves clinical outcomes, enhances safety, or drives incremental improvements to health care delivery or business models. The CareView Patient Safety System leverages CareView’s patented Virtual Bed Rails and Virtual Chair Rails, which use machine learning to differentiate between normal patient movements and behaviors of an at-risk patient. Exclusive integrations with the health system’s electronic health record (EHR) and nurse communication systems allow for enhanced clinical workflows and improved response times. With CareView’s system, one staff member can safely monitor and interact with up to 40 patients, resulting in fewer false alarms, quicker staff interventions, and a significant reduction in patient falls. “We are very excited to bring our CareView Patient Safety System to the Vizient Innovative Technology Exchange. CareView’s latest equipment will address hospital staffing shortages, ease care burdens, and improve care efficiency by having a virtual sitter in every at-risk and high acuity patient room.” Sandra McRee, CareView’s Chief Operating Officer “Suppliers come to the Exchange hoping to be awarded an Innovative Technology contract, which signals health care providers of their product’s unique qualities,” said Kelly Flaharty, director of contract process, Vizient. “We are pleased to include CareView’s technology in the group selected to participate.” The annual Innovative Technology Exchange is part of Vizient’s Innovative Technology Program that includes product review of supplier-submitted technologies by member-led councils and task forces. Since 2003, Vizient has reviewed over 1,600 product submissions as part of its Innovative Technology Program. About CareView Communications, Inc. As a leader in turnkey patient video monitoring solutions, CareView is redefining the standard of patient safety in hospitals and healthcare facilities across the country. For over a decade, CareView has relentlessly pursued innovative ways to increase patient protection, providing next generation solutions that lower operational costs and foster a culture of safety among patient, staff and hospital leadership. With installations in more than 150 hospitals, CareView has proven that its innovative technology is creating a culture of patient safety where patient falls have decreased by 80% with sitter costs reduced by more than 65%. Anchored by the CareView Patient Safety System, this modular, scalable solution delivers flexible configurations to fit any facility while significantly increasing patient safety and operational savings. All configurations feature HD cameras, high-fidelity 2-way audio/video, LCD displays for the ultimate in capability, flexibility, and affordability. Corporate offices are located at 405 State Highway 121 Bypass, Suite B-240, Lewisville, TX 75067.

Read More

FUTURE OF HEALTHCARE

Winner Medical Acquires Majority Stake in Pingan Medical to Fuel Growth

Winner Medical | June 02, 2022

Winner Medical Co. Ltd. a leading manufacturer of disposable wound care and surgical products, announced on May 18 that it will acquire a majority 65.55% stake in Hunan Pingan Medical Device Technology Co. Ltd. for 652 million yuan as the Company continues to expand its disposable medical supply lineup. Upon the completion of the deal, Winner Medical is set to hold a total of 68.7% stake in Pingan Medical for a total of 752 million yuan. The Company's move comes as it looks to make a foray into the field of injection products to diversify its product offerings besides consumer products, and comes in line with its strategy to provide one-stop disposable medical supply solutions. Established in 2010, Pingan Medical mainly produces disposable medical devices, such as syringes, infusion sets, and blood collection tubes among other medical supplies. In 2021, Pingan Medical recorded 360 million yuan in revenue and booked a net profit of 85 million yuan. The acquisition will leverage both companies' strengths and help fill the product gap in injection-related disposables of Winner Medical, enabling it to expand into new medical verticals and achieve its goal of becoming a major supplier for the domestic market. Specifically, the Company plans to roll out medical sets that comprise needle-type products from Pingan Medical and wound care supplies from Winner Medical, providing one-stop customized solutions for hospitals and large medical centers. Meanwhile, Winner Medical will help Pingan Medical with its industry-leading R&D capabilities to develop medical device solutions and build smart manufacturing plants. To fuel the growth based on the new deal, Winner Medical has signed an investment note with the local government of Li County in Hunan Province, where Pingan Medical is headquartered, to build medical equipment production lines, smart warehousing, and R&D facilities. The latest deal follows Winner Medical's April-11 acquisition of wound dressing maker Zhejiang Longterm Medical Technology Co. Ltd. as part of its expansion strategy to stay competitive in the area of high-end wound dressings. The Company has also set up a dedicated team to promote its self-developed wound dressing products as the market for such medical supplies is still in its infancy in China. Founded in 1991, Winner Medical has made efforts to offer quality cotton-based medical dressings and disposables, and will continue to push ahead with its strategy to diversify its product lineup and boost consumption. On the manufacturing front, the Company aims to expand to new medical verticals through acquisitions, while on the consumption front, it plans to enhance product sales through digitization and gradually phasing out less popular products. As such, the Company has made significant progress in digitizing its operations. Winner Medical has gone live on multiple e-commerce platforms, and has gone digital in terms of online and offline warehousing and order management.

Read More

HEALTH TECHNOLOGY

H2O.ai Showcases Healthcare and Life Sciences Leadership with Customer Successes, Breadth of AI Apps at HIMSS 2022

H2O.ai | March 14, 2022

H2O.ai, the AI Cloud leader, announced it has expanded its healthcare capabilities, now offering 40 AI applications across population health, precision medicine, public health and intelligent supply chain, supporting customers throughout the healthcare ecosystem including Bon Secours Mercy Health and Kaiser Permanente. The company will demonstrate its technologies at the healthcare industry’s flagship technology conference, HIMSS, in Booth No. 8141, March 15-17 at the Orange County Convention Center in Orlando. Healthcare and life sciences organizations have been stretched thin over the past few years and are actively looking for new technologies to streamline operations and improve patient outcomes across the private and public sectors. AI will empower physicians, hospital administrators, researchers and pharmaceutical companies with models and applications that produce more affordable, more accessible and more efficient healthcare. H2O.ai is at the forefront of this effort, helping organizations rapidly transform to improve health equity, access and care. For example, the Center for Digital Health Innovation (CDHI) at the University of California, San Francisco (UCSF) is collaborating with H2O.ai on the development and training of AI algorithms that automate the processing of the 1.4 million faxed patient referrals and other documents that UCSF’s health system receives annually. The algorithms identify, classify and prioritize document types. For referrals, the AI extracts key patient data, history and relevant health information that will assist staff and eliminate manual data entry and validation tasks. “AI in healthcare has the potential to dramatically improve the operational processes that can prevent patients from getting care quickly, at the right place, and from the right provider. Our work with H2O.ai for health document handling is just one aspect of the transformation in the ways patients access and receive care.” Alon Konchitsky, associate director for data science and machine learning at CDHI H2O.ai has developed 40 AI apps supporting various components of the healthcare ecosystem, including Population Health H2O.ai’s Covid-19 hospital occupancy simulator allows hospital administrators to track, predict and manage Covid-19-related hospital admissions by U.S. county. The company also has a pop-up predictor that allows for the quick identification of specific addresses in the U.S. that would be most suitable for temporary vaccination clinics, mobile testing centers, public education stands and more. H2O.ai’s customers - leading providers, payers and accountable care organizations (ACOs) - are developing and deploying AI models and apps around patient no shows, 30-day readmission predictors, risk stratification and omni-channel patient engagement NLP. Precision Medicine H2O.ai has developed a gene mutation app, a machine learning-powered patient risk assessment application that uses the Snowflake Data Cloud and the H2O AI Cloud to bring intelligent clinical decision support directly to clinicians. In another use case, H2O.ai’s gene expression tumor classification app uses gene expression information from patient biopsies to evaluate the risk of malignancy and understand how common the risk has been among past patients. “H2O AI Cloud, integrated with the Snowflake Data Cloud, is making it easier for health organizations to rapidly develop precision medicine solutions,” said Todd Crosslin, Global Head of Healthcare and Life Sciences at Snowflake. “The Gene mutation app is just the beginning of our health partnership and our ability to deliver improved care and patient outcomes.” Public Health The company’s Covid-19 forecasting application enables hospital staff, policymakers and others to predict the next wave of infection as well as potential case and death rates. H2O.ai also provides a vaccine sentiment tool that leverages natural language processing (NLP) to understand the sentiment around Covid-19 vaccines, and the company is currently working with leaders to address the risks and care associated with PASC (AKA Long COVID). Intelligent Supply Chain To provide intelligent supply chain support, H2O.ai’s route optimizer application helps health manufacturers best optimize transportation routes to ensure products arrive on time and to standard. H2O.ai also has developed an order and inventory management app to aid health manufacturers’ inefficient warehouse and inventory management decisions. Avoiding AI “Pilot-itis” Many health and life sciences organizations are struggling to implement AI projects that improve patient outcomes, reduce costs and more. Through its expertise and the H2O AI Cloud platform, H2O.ai is able to break companies out of the pilot cycle and successfully take them to AI maturity to deliver impactful results. In fact, H2O.ai has experienced an increase in healthcare customers moving from the pilot phase to full-blown production AI programs. “Artificial Intelligence and deep learning are not only driving the latest innovations in medicine but also are enabling healthcare organizations to connect fragmented data into a format that can be used to improve operational efficiency and provide more user-centric patient experiences,” said Sri Ambati, CEO and co-founder of H2O.ai. “From its use in drug discovery and forecasting the next COVID-19 variant to streamlining supply chain operations and reducing healthcare worker churn, AI will have a significant impact on democratizing health and improving patient outcomes.” About H2O.ai H2O.ai is the leading AI cloud company, on a mission to democratize AI for everyone. Customers use the H2O AI Cloud platform to rapidly solve complex business problems and accelerate the discovery of new ideas. H2O.ai is the trusted AI provider to more than 20,000 global organizations, including AT&T, Bon Secours Mercy Health, Capital One, Commonwealth Bank of Australia, GlaxoSmithKline, Hitachi, Kaiser Permanente, Procter & Gamble, PayPal, PwC, Reckitt, Unilever and Walgreens, over half of the Fortune 500 and one million data scientists. Goldman Sachs, NVIDIA and Wells Fargo are not only customers and partners, but strategic investors in the company. H2O.ai’s customers have honored the company with a Net Promoter Score (NPS) of 78— the highest in the industry based on breadth of technology and deep employee expertise. The world’s top 20 Kaggle Grandmasters (the community of best-in-the-world machine learning practitioners and data scientists) are employees of H2O.ai. A strong AI for Good ethos to make the world a better place and Responsible AI drive the company’s purpose. Please join our movement at H2O.ai.

Read More

Spotlight

Expose the bony anatomy of the femur and tibia. Prepare the anatomy in the usual fashion by removing as much soft tissue around the femur and tibia as needed to allow for good exposure and optimal Signature MRI-based femoral and tibial positioning guide registration. Register the Signature MRI-based femoral positioning guide on the femur. The Signature MRI-based femoral guide is designed to register in one unique location on cartilage, where present, and on bone where cartilage is absent.

Resources